Larsson Peter, Nordlinder Anders, Bergendahl Henrik T G, Lönnqvist Per-Arne, Eksborg Staffan, Almenrader Nicole, Anderson Brian J
Department of Physiology & Pharmacology, Section of Anaesthesiology & Intensive Care, Karolinska Institutet, Stockholm, Sweden.
Paediatr Anaesth. 2011 Mar;21(3):335-40. doi: 10.1111/j.1460-9592.2010.03397.x. Epub 2010 Aug 24.
Oral clonidine is used as premedication in children. The bioavailability of clonidine given orally in adults is 75-100% but is unknown in children.
Children (3-10 years) undergoing adenotonsillectomy were administered oral clonidine 4 mcg·kg(-1) mixed with apple fruit drink as premedication. Intravenous plasma was assayed for clonidine concentration at 5, 15, 30, 45 min and 1, 2, 4, 6, 12, 18 h after administration. Clonidine plasma concentrations were determined by liquid chromatography-mass spectroscopy, and pharmacokinetic parameters were calculated using nonlinear effects mixed-effects models. Current data were pooled with published time-concentration profiles from children (n = 49) administered intravenous clonidine to determine oral bioavailability.
There were eight children studied (age 3-10 years, weight 10.5-36 kg). A two-compartment model with first-order absorption and elimination was used to describe time-concentration profiles. Population parameter estimates (CV%; 95% CI), standardized to a 70-kg person, were absorption half-life (Tabs), 0.45 (85.1; 0.221-0.884) h, absorption lag time (Tlag), 0.148 (91.2; 0.002-0.316) h, Clearance (CL) 17.9 (30.3; 16-20.3) l·h(-1) per 70 kg, between compartment clearance (Q) 121 (44.3; 80.1-165) l·h(-1) per 70 kg, central volume (V1) 81.2 (71.5; 60.7-105) l·70 kg(-1), peripheral volume of distribution (V2) 113 (33.9; 91-131) l·70 kg(-1). The oral bioavailability was 55.4% (CV 6.4%; 95% CI 0.469, 0.654).
Clonidine administered with an apple fruit drink displays a variable and relatively slow absorption after oral administration (T(max) 1.04 h, C(max) 0.77 mcg·l(-1)). The oral bioavailability was 55.4%, which is less than reported in adults. Consequently, higher oral doses of clonidine (per kg) are required when this formulation is used to achieve concentrations similar to those reported in adults.
口服可乐定用于儿童术前用药。可乐定在成人口服后的生物利用度为75%-100%,但在儿童中尚不清楚。
对接受腺样体扁桃体切除术的3至10岁儿童,给予口服可乐定4 mcg·kg⁻¹并与苹果果汁饮料混合作为术前用药。在给药后5、15、30、45分钟以及1、2、4、6、12、18小时采集静脉血样,检测血浆可乐定浓度。通过液相色谱-质谱法测定可乐定血浆浓度,并使用非线性效应混合效应模型计算药代动力学参数。将当前数据与已发表的静脉注射可乐定儿童(n = 49)的时间-浓度曲线合并,以确定口服生物利用度。
共研究了8名儿童(年龄3至10岁,体重10.5至36 kg)。采用具有一级吸收和消除的二室模型来描述时间-浓度曲线。以体重70 kg的人为标准,群体参数估计值(CV%;95% CI)为:吸收半衰期(Tabs)0.45(85.1;0.221-0.884)小时,吸收滞后时间(Tlag)0.148(91.2;0.002-0.316)小时,清除率(CL)每70 kg为17.9(30.3;16-20.3)l·h⁻¹,室间清除率(Q)每70 kg为121(44.3;80.1-165)l·h⁻¹,中央室容积(V1)81.2(71.5;60.7-105)l·70 kg⁻¹,外周分布容积(V2)113(33.9;91-131)l·70 kg⁻¹。口服生物利用度为55.4%(CV 6.4%;95% CI 0.469,0.654)。
与苹果果汁饮料一起服用的可乐定口服后吸收可变且相对缓慢(T(max) 1.04小时,C(max) 0.77 mcg·l⁻¹)。口服生物利用度为55.4%,低于成人报道的数值。因此,当使用该制剂达到与成人报道相似的浓度时,需要更高的可乐定口服剂量(每千克)。